KDK13901
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
CAS: 910463-68-2, Semaglutide, Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone., PMID:40515833
[Weight reduction with incretin mimetics-Opportunities and risks]., PMID:40514554
A biodegradable suction patch for sustainable transbuccal peptide delivery., PMID:40513668
Controversies in nomenclature: From nonalcoholic steatohepatitis to the full spectrum of hepatic steatosis., PMID:40513177
2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology., PMID:40512113
Addressing obesity and subsequent cardiovascular risk in primary care: the relevance of high- and low-resource settings., PMID:40512090
Key takeaways from the updated multidisciplinary European MASLD guidelines., PMID:40510733
Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes., PMID:40510603
Oral semaglutide for the treatment of obesity: a retrospective real-world study., PMID:40510489
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies., PMID:40507553
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia., PMID:40506208
Semaglutide for clozapine-treated patients with schizophrenia., PMID:40506202
Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data., PMID:40503067
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol., PMID:40502777
Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes., PMID:40502555
Effect of Semaglutide on C-peptide levels in patients with type 2 diabetes., PMID:40501244
Semaglutide-A ray of hope for CKD in diabetic patients., PMID:40500852
Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide., PMID:40499315
The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment., PMID:40497223
Clinical Profile and Prognosis of Patients With Acute Decompensated Heart Failure Who Met the Obesity-Related Eligibility for Subcutaneous Semaglutide - Findings From the CURE-HF Registry., PMID:40497126
Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD., PMID:40496439
Finerenone and semaglutide: Role in heart failure with reduced ejection fraction., PMID:40496391
Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms., PMID:40494410
Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations., PMID:40493329
Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis., PMID:40493069
Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status., PMID:40491239
Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics., PMID:40490304
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database., PMID:40490170
Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery., PMID:40490042
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis., PMID:40489581
External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes., PMID:40489337
Worth the Weight? The Challenges of Administering the Glucagon-Like Peptide 1 Receptor Agonist Semaglutide With Long-Term Olanzapine Use in a Patient With Schizophrenia., PMID:40488719
Association of GLP-1 Receptor Agonists with Liver-Related Outcomes and All-Cause Mortality in Patients with Harmful Alcohol Use: A Target Trial Emulation Study., PMID:40488647
Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea., PMID:40487675
Pregnancy outcomes following first trimester exposure to semaglutide., PMID:40487375
Improved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: a promising new addition to preoperative optimization., PMID:40486798
Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study., PMID:40486301
GLP-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate PAD., PMID:40484062
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial., PMID:40482671
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial., PMID:40482670
The Obesity Paradox of Cardiovascular Outcomes in Patients with Diabetes Mellitus., PMID:40481922
Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial., PMID:40478570
Research letter: the global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD) current status and future prospects., PMID:40474833
Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels., PMID:40473254
CROI 2025: neuropsychiatric complications in people with HIV., PMID:40472384
Prescriptions for Obesity Medications Among Adolescents Aged 12-17 Years with Obesity - United States, 2018-2023., PMID:40471858
Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial Cardiomyocytes., PMID:40471762
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis., PMID:40471293
Letter: Amiodarone-Induced Thyrotoxicosis Following Semaglutide-Associated Weight Loss., PMID:40470537
Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: A propensity-score matched analysis., PMID:40470002
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
